Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia

The outcome of older (≥ 60 years) acute myeloid leukemia (AML) patients is poor, and novel treatments are needed. In a phase 2 trial for older AML patients, low-dose (20 mg/m(2) per day for 10 days) decitabine, a DNA hypomethylating azanucleoside, produced 47% complete response rate with an excellen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yan, Pearlly, Frankhouser, David, Murphy, Mark, Tam, Hok-Hei, Rodriguez, Benjamin, Curfman, John, Trimarchi, Michael, Geyer, Susan, Wu, Yue-Zhong, Whitman, Susan P., Metzeler, Klaus, Walker, Alison, Klisovic, Rebecca, Jacob, Samson, Grever, Michael R., Byrd, John C., Bloomfield, Clara D., Garzon, Ramiro, Blum, William, Caligiuri, Michael A., Bundschuh, Ralf, Marcucci, Guido
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2012
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3448258/
https://ncbi.nlm.nih.gov/pubmed/22786882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-429175
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados